1,500 radiation therapy centers choose myQA

IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announced at the ESTRO 38 congress, that it has reached the milestone of 1,500 myQA customers worldwide. Since the first release of myQA in 2015, IBA has rapidly expanded its customer base across the global radiation therapy community and today serves the largest QA platform customer base by far. This growth has been driven by the need to improve the integration of quality assurance across all QA applications, departments, and professionals in radiation therapy and beyond.

With myQA, IBA Dosimetry has been the innovation leader for quality assurance platform solutions and has set a new standard in making quality checks for cancer treatments safer and more efficient. Compared to other solutions, myQA integrates all modern radiation therapy QA needs, from Beam Scanning and Machine QA, to Imaging QA and Patient QA. The generic test functionality enables users to integrate their individual site-specific tests into the global QA platform "In 2015, IBA Dosimetry has introduced the world’s first quality assurance platform solution to the radiation therapy market. With a very fast market adoption, over 1,500 healthcare centers worldwide trust myQA today,” said Jean-Marc Bothy, President of IBA Dosimetry. “This success is also an incentive for us and our collaboration partners to continue lead QA innovations into the future. With continued enhancements and additional functionality we are enabling medical physicists and radiation therapy experts around the world to provide more efficient QA and safer patient treatments.”

29.04.2019

• radiation protection (181)
• radiation therapy (148)

• IBA Dosimetry GmbH